NVNO enVVeno Medical Corporation

enVVeno Medical, formerly Hancock Jaffe Laboratories, specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValve“, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraft“, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.

$6.23
As of 12/03/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Medical Devices
Index country:  USA
Country of incorporation:  
IPO date:  05/31/2018
Outstanding shares:  9,468,324
Average volume:  82,140
Market cap:   $59,934,491
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.02
PS ratio:   0.00
Return on equity:   -20.52%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy